Hot Features
Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutrali... Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California. Mehr anzeigen
Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced...
Expect to initiate Phase 2 studies evaluating tibulizumab for the treatment of systemic sclerosis (SSc) in Q4 2024 and hidradenitis suppurativa (HS) in Q2 2025 Cash, cash equivalents and...
Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -1.3803 | -30.3362637363 | 4.55 | 4.85 | 3.1697 | 382248 | 4.21669211 | CS |
| 4 | -1.7203 | -35.1799591002 | 4.89 | 5.07 | 3.1697 | 340098 | 4.44939829 | CS |
| 12 | -0.4203 | -11.7075208914 | 3.59 | 5.07 | 3.1697 | 453543 | 4.24217242 | CS |
| 26 | -2.0603 | -39.3938814532 | 5.23 | 6.35 | 3.14 | 357960 | 4.10901854 | CS |
| 52 | -1.1603 | -26.7967667436 | 4.33 | 6.35 | 2 | 306954 | 3.87017579 | CS |
| 156 | -4.8303 | -60.37875 | 8 | 37.55 | 2 | 341653 | 6.58212303 | CS |
| 260 | -4.8303 | -60.37875 | 8 | 37.55 | 2 | 341653 | 6.58212303 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
